AcuMEMS Appoints Richard M. Ferrari to Board

MENLO PARK, Calif.--(BUSINESS WIRE)-- AcuMEMS, Inc. today announced the appointment of Richard M. Ferrari as a new member of its Board of Directors.

Commenting on his appointment, Richard Ferrari said, “I am pleased to join the Board at this exciting time in the company’s development. The company’s products fundamentally change the practice of glaucoma and implanting the sensor is familiar and fast for eye surgeons.”

Richard M. Ferrari is a Managing Director of De Novo Ventures, a healthcare investment firm with $650 million total assets under management. Mr. Ferrari was a successful CEO of several medical technology companies before co-founding De Novo in 2000. He was co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was acquired by Guidant Corporation in 1999. Before that, he was CEO of Cardiovascular Imaging Systems, where he orchestrated a successful IPO and later sale to Boston Scientific Corporation in 1995.

Douglas Lee, Chairman and CEO of AcuMEMS, added, “Rich has demonstrated his skill at building successful device companies over a long period of time, and as a result, is one of the most respected people in the industry. Without question, he will accelerate the growth of AcuMEMS into a significant ophthalmic business based on the principle of wireless direct IOP measurement.”

About AcuMEMS

AcuMEMS, Inc. (Menlo Park, California) is a medical device company that is developing the iSense System for the management and treatment of glaucoma, the leading cause of irreversible blindness worldwide. The iSense System, comprising a portfolio of implantable MEMS (Micro-Electro-Mechanical-Systems) sensors that couple to a handheld reader, enables wireless and direct measurement of intraocular pressure (IOP). This new capability transforms disease management of glaucoma by facilitating IOP monitoring and treatment to a prescribed targeted pressure by the ophthalmologist.

AcuMEMS is an affiliate company of OrthoMEMS, Inc.



CONTACT:

AcuMEMS, Inc.
Douglas Lee, CEO, 650-380-3759

KEYWORDS:   United States  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Medical Devices  Medical Supplies

MEDIA:

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.